Company intelligence / Profile preview

AdopTracell

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

AdopTracell is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to developing innovative adoptive cell therapies for solid tumors. The company leverages its proprietary AdopTracell platform to engineer T-cells with improved infiltration and sustained activity within the immunosuppressive tumor microenvironment. Its lead programs include CAR-T therapies targeting Mesothelin and GPC3, which are currently being evaluated for safety and efficacy in various solid malignancies. By focusing on T-cell fitness and metabolic reprogramming, AdopTracell aims to overcome the historical challenges of cell therapy in non-hematological cancers.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on AdopTracell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdopTracell.

Explore the full profile